Featured
Novartis plans to axe 680 employees
Novartis declared plans to lay off approximately 680 staff members in its development organisation on 9 April. The workforce reductions…
Pluri launches manufacturing division as cell therapy pipeline progresses
Israeli cell technology company Pluri has expanded its cell-based product operations in a bid to support other companies with their…
Incannex prepares IND submission for psychotherapy asset
Incannex Healthcare is gearing up for an investigational new drug (IND) submission for a Phase IIb generalised anxiety disorder study…
Ipsen joins the ADC club with deal worth up to $900m
Ipsen has joined the slew of companies developing antibody-drug conjugates (ADC) with the announcement of a new global licensing agreement…
Xilio and Gilead partner up for IL-12 therapeutic development
Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement for the development of a tumour-activated IL-12 program. Under the…